{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:51:44Z","timestamp":1784242304541,"version":"3.55.0"},"reference-count":127,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":97,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:p>Thrombosis is an underlying cause of many cardiovascular disorders, and generation of thrombi in the arterial circulation can lead to unstable angina, myocardial infarction, or ischemic stroke. Antithrombotic therapy is widely used, with proven benefit to prevent ischemic stroke and thromboembolic events in patients with atrial fibrillation (AF) or to prevent further ischemic complications in patients with acute coronary syndrome (ACS). Traditional anticoagulants (including unfractionated heparin, low\u2010molecular\u2010weight heparin, and warfarin) and antiplatelet agents (including aspirin, clopidogrel, and prasugrel) are typically used for these indications. Limitations to their use include variable pharmacokinetic and pharmacodynamic profiles, inability to inhibit fibrin\u2010bound thrombin, risk of heparin\u2010induced thrombocytopenia, delayed onset of action, numerous drug interactions, need for substantial laboratory monitoring and dosage titrations, hyporesponsiveness or resistance, hypersensitivity, adverse events, and bleeding. To overcome some of the limitations of traditional agents, new antithrombotic agents under development are highly selective for specific coagulation factors blocking the synthesis of thrombin. Clinicians must have an understanding of the new anticoagulants to aid in the selection of appropriate therapies for patients. We describe the most relevant phases II and III clinical trials that evaluated several recent emerging anticoagulant drugs for use in patients with AF or ACS. The advantages of many new agents include predictable pharmacodynamic response and pharmacokinetic parameters, allowing for fixed oral dosing with no need for laboratory monitoring. For patients with AF, dabigatran is already approved for the prevention of stroke and systemic embolism, rivaroxaban appears to be an effective alternative to warfarin in high\u2010risk patients, and apixaban may also be an effective alternative to aspirin in patients unable to take warfarin. Otamixaban shows promise as an intravenous alternative for patients with ACS in the acute care setting. Likewise, rivaroxaban, dabigatran, and darexaban with or without dual antiplatelet therapy may be beneficial for secondary prevention of ischemic events in patients with ACS.<\/jats:p>","DOI":"10.1592\/phco.31.10.975","type":"journal-article","created":{"date-parts":[[2011,9,27]],"date-time":"2011-09-27T22:40:29Z","timestamp":1317163229000},"page":"975-1016","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["New and Emerging Anticoagulant Therapy for Atrial Fibrillation and Acute Coronary Syndrome"],"prefix":"10.1002","volume":"31","author":[{"given":"Estella M.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen A.","family":"Packard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon T.","family":"Knezevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eul097"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31820f14c0"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq278"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192663"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.02.013"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"S546","DOI":"10.1378\/chest.08-0678","article-title":"Antithrombotic therapy in atrial fibrillation","volume":"133","author":"Singer DE","year":"2008","journal-title":"Chest"},{"key":"e_1_2_1_8_2","first-page":"1449","article-title":"Meta\u2010analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"154","author":"Hart RG","year":"1994","journal-title":"Ann Intern Med"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1994.00420130036007"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S12056"},{"key":"e_1_2_1_11_2","unstructured":"The Medicines Company.Angiomax (bivalirudin) package insert. Parsippany NJ;2010."},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm575"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-009-0392-5"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0673"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.8.2308"},{"key":"e_1_2_1_16_2","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc.Pradaxa (dabigatran) package insert. Ridgefield CT;2011."},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.76.1.142"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309023291001"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"e_1_2_1_20_2","unstructured":"Bayer Schering Pharma AG. Xarelto (rivaroxaban) European package insert. Berlin Germany;2008."},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/0003088-200948010-00001"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-011-0561-1"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp318"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.856120"},{"key":"e_1_2_1_25_2","first-page":"743","article-title":"Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants","volume":"50","author":"Bavisotto LM","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_1_26_2","first-page":"1","article-title":"Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor\u2014interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"Ryn JV","year":"2010","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.09.017"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02899.x"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03753.x"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-011-0559-8"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01230.x"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.202978"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800374"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa076016"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60880-6"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60734-0"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"e_1_2_1_39_2","unstructured":"CohenAT.Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients.Presented at the American College of Cardiology annual conference New Orleans LA April 25 2011."},{"key":"e_1_2_1_40_2","volume-title":"BAY59\u20137939 in atrial fibrillation once daily (OD). Updated 2008. ClinicalTrials.gov","author":"Bayer.","year":"2011"},{"key":"e_1_2_1_41_2","volume-title":"BAY59\u20137939 Japanese in atrial fibrillation (2nd). Updated 2010. ClinicalTrials.gov","author":"Bayer.","year":"2011"},{"key":"e_1_2_1_42_2","volume-title":"BAY59\u20137939, Japanese phase II in atrial fibrillation trial status. Updated 2008. ClinicalTrials.gov","author":"Bayer.","year":"2011"},{"key":"e_1_2_1_43_2","volume-title":"Efficacy and safety of rivaroxaban for the prevention of stroke in subjects with non\u2010valvular atrial fibrillation. Updated 2010. ClinicalTrials.gov","author":"Bayer.","year":"2011"},{"key":"e_1_2_1_44_2","unstructured":"PatelMR for ROCKET AF Executive Steering Committee.Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with non\u2010valvular atrial fibrillation [abstract].American Heart Association Late\u2010Breaking Clinical Trials II November 15 2010 abstract 21839."},{"key":"e_1_2_1_45_2","unstructured":"MahaffeyKW FoxKA for the ROCKET AF Investigators.Rivaroxaban once\u2010daily oral direct factor Xa inhibition compared with vitamin K antagonism for the prevention of stroke and embolism trial in atrial fibrillation: ROCKET AF 2010. Available fromhttp:www.cardio.sefileArchiveFilerAHA\u20102010\u2010ChicagoROCKET\u2010A.pdf. AccessedJanuary 31 2011."},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.11.025"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60738-8"},{"key":"e_1_2_1_48_2","volume-title":"An efficacy and safety study for rivaroxaban in patients with acute coronary syndrome. Updated 2011. ClinicalTrials.gov","author":"Johnson & Johnson Pharmaceutical Research and Development, L.L.C.","year":"2011"},{"key":"e_1_2_1_49_2","unstructured":"U.S. Food and Drug Administration.FDA news release: FDA approves Xarelto to reduce risk of blood clots after hip knee replacements. Available fromhttp:www.fda.govNewsEventsNewsroomPressAnnouncementsucm261839.htm. AccessedJuly 27 2011."},{"key":"e_1_2_1_50_2","unstructured":"Johnson & Johnson.New drug application submitted to FDA for rivaroxaban for prevention of stroke in patients with atrial fibrillation January 5 2011. Available fromhttp:www.jnj.comconnectnewsallnew\u2010drug\u2010application\u2010submitted\u2010to\u2010fda\u2010for\u2010rivaroxaban\u2010for\u2010prevention\u2010of\u2010stroke\u2010in\u2010patients\u2010with\u2010atrial\u2010fibrillation. AccessedMay 5 2011."},{"key":"e_1_2_1_51_2","unstructured":"U.S. Food and Drug Administration.September 8 2011: cardiovascular and renal drugs advisory committee meeting announcement. Available fromhttp:www.fda.govAdvisoryCommitteescalendarucm261963.htm. AccessedJuly 27 2011."},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-009-0421-4"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.029694"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-008-9210-9"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.10.5"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02764.x"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62125-5"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03054.x"},{"key":"e_1_2_1_59_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.31.31","article-title":"Randomized double\u2010blind comparison of apixaban with enoxaparin for thromboprophylaxis after knee replacement: the ADVANCE\u20101 trial [abstract]","volume":"112","author":"Lassen M.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1006885"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007432"},{"key":"e_1_2_1_62_2","volume-title":"Apixaban for the prevention of stroke in subjects with atrial fibrillation (ARISTOTLE). Updated 2011. ClinicalTrials.gov","author":"Bristol\u2010Myers Squibb","year":"2011"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.832139"},{"key":"e_1_2_1_64_2","unstructured":"AlexanderJH LopesRD JamesS. for the APPRAISE\u20102 Investigators.Apixaban with antiplatelet therapy after acute coronary syndrome [published online ahead of print July 24 2011]. N Engl J Med. Available fromhttp:dx.doi.org10.1056NEJMoa1105819."},{"key":"e_1_2_1_65_2","volume-title":"A study to evaluate the safety of apixaban in acute coronary syndrome (ACS) Japanese patients. Updated 2011. ClinicalTrials.gov","author":"Pfizer, Inc.","year":"2011"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.07.035"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009351883"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010370974"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-07-0451"},{"key":"e_1_2_1_70_2","article-title":"Effect of renal function on edoxaban pharmacokinetics (PK) and on population PK\/PK\u2010PD model [abstract]","volume":"49","author":"Ridout G.","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_1_71_2","article-title":"Edoxaban in patients undergoing total hip arthroplasty: a phase IIb dose\u2010finding study [abstract]","volume":"112","author":"Fuji T.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_1_72_2","unstructured":"FujiT.Edoxaban versus enoxaparin for thromboprophylaxis after total knee replacement: the STARS E\u20103 trial.Presented at the 21st international congress of thrombosis Milan Italy July 69 2010."},{"key":"e_1_2_1_73_2","doi-asserted-by":"crossref","unstructured":"FujiT. FujitaS. TachibanaS.Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J\u2010V trial.Presented at the annual meeting of the American Society of Hematology Orlando FL December 47 2010.","DOI":"10.1182\/blood.V116.21.3320.3320"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-01-0066"},{"key":"e_1_2_1_75_2","volume-title":"Global study to assess the safety and effectiveness of DU\u2010176b vs standard practice of dosing with warfarin in patients with atrial fibrillation (EngageAFTIMI48). Updated 2010. ClinicalTrials.gov","author":"Daiichi Sankyo, Inc.","year":"2011"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.06.042"},{"key":"e_1_2_1_77_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1160\/TH08-07-0460","article-title":"A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)","volume":"101","author":"Turpie AG","year":"2009","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_78_2","unstructured":"EzekowitzMD ConnollySJ DiazR. HohnloserSH DorianP.A phase 2 randomized parallel group dose finding multicenter multinational study of the safety tolerability and pilot efficacy of three blinded doses of the oral factor Xa inhibitor betrixaban compared with open\u2010label dose\u2010adjusted warfarin in patients with non\u2010valvular atrial fibrillation (EXPLORE\u2010Xa).Presented at the American College of Cardiology annual scientific sessions Atlanta GA March 1416 2010."},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-07-0434"},{"key":"e_1_2_1_80_2","unstructured":"StringerF. ScottG. KupferS. et al.The pharmacokinetics and pharmacodynamics of TAK\u2010442 an oral direct factor Xa inhibitor following multiple dosing in healthy male subjects [abstract]. In:British Pharmacological Society Winter Conference Proceedings2009: abstract CP026."},{"key":"e_1_2_1_81_2","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood.V114.22.4175.4175","article-title":"Absence of pharmacodynamic or pharmacokinetic interactions when TAK\u2010442, an oral, direct factor Xa inhibitor, is co\u2010administered with aspirin or clopidogrel [abstract]","volume":"114","author":"Stringer F.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2010.04.005"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e31820382a9"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-05-0273"},{"key":"e_1_2_1_85_2","volume-title":"Safety and efficacy of TAK\u2010442 in subjects with acute coronary syndromes. Updated 2010. ClinicalTrials.gov","author":"Takeda Global Research and Development Center, Inc.","year":"2011"},{"key":"e_1_2_1_86_2","unstructured":"Takeda Pharmaceutical Co.Takeda announces top line results from phase 2 study of investigational compound TAK\u2010441 for patients with ACS. Press release October 26 2010. Available fromhttp:www.takeda.compressarticle_38715.html. AccessedApril 30 2011."},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03748.x"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02644.x"},{"key":"e_1_2_1_89_2","volume-title":"A study evaulating safety and tolerability of YM150 compared to warfarin in subjects with atrial fibrillation (OPAL\u20102). Updated 2011. ClinicalTrials.gov","author":"Astellas Pharma, Inc.","year":"2011"},{"key":"e_1_2_1_90_2","volume-title":"Direct factor Xa inhibitor YM150 for prevention of stroke in subjects with non\u2010valvular atrial fibrillation. Updated 2009. ClinicalTrials.gov","author":"Astellas Pharma, Inc.","year":"2011"},{"key":"e_1_2_1_91_2","volume-title":"Study evaluating safety, tolerability, and efficacy of YM150 in subjects with acute coronary syndromes (RUBY\u20101). Updated 2010. ClinicalTrials.gov","author":"Astellas Pharma, Inc.","year":"2011"},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005281817"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61454-9"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.09.002"},{"key":"e_1_2_1_95_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.653428"},{"key":"e_1_2_1_96_2","unstructured":"Sanofi\u2010aventis.Effect of otamixaban versus unfractionated heparin + eptifibatide in patients with unstable angina\/non ST elevation myocardial infarction undergoing early invasive strategy (TAO). Updated 2011. ClinicalTrials.gov. Available fromhttp:clinicaltrials.govct2showNCT01076764termNCT01076764&rank1. AccessedMay 5 2011."},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062437"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.04.036"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14841-6"},{"key":"e_1_2_1_100_2","unstructured":"The electronic Medicines Compendium (eMC).Pradaxa 110 mg hard capsules: summary of product characteristics. Available fromhttp:www.medicines.org.ukguidespradaxaBlood20clottingpradaxa20110mg20capsules. AccessedMay 1 2011."},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.06.034"},{"key":"e_1_2_1_102_2","volume-title":"A dose response study of dabigatran etexilate (BIBR 1048) in pharmaco\u2010dynamics and safety in patients with non\u2010valvular atrial fibrillation in comparison to warfarin. Updated 2011. ClinicalTrials.gov","author":"Boehringer Ingelheim Pharmaceuticals.","year":"2011"},{"key":"e_1_2_1_103_2","volume-title":"Long\u2010term, open\u2010label follow\u2010up treatment of patients with A\u2010fib who have been previously treated with BIBR 1048. Updated 2011. ClinicalTrials.gov","author":"Boehringer Ingelheim Pharmaceuticals.","year":"2011"},{"key":"e_1_2_1_104_2","volume-title":"RELY\u2010ABLE long term multi\u2010center extension of dabigatran treatment in patients with atrial fibrillation who completed RE\u2010LY trial. Updated 2011. ClinicalTrials.gov","author":"Boehringer Ingelheim Pharmaceuticals.","year":"2011"},{"key":"e_1_2_1_105_2","first-page":"2160","article-title":"Randomized dabigatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel (RE\u2010DEEM) [abstract]","volume":"120","author":"Oldgren J.","year":"2009","journal-title":"Circulation"},{"key":"e_1_2_1_106_2","volume-title":"Randomized, open label study of dabigatran etexilate in elective percutaneous coronary intervention. Updated 2011. ClinicalTrials.gov","author":"Boehringer Ingelheim Pharmaceuticals.","year":"2011"},{"key":"e_1_2_1_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.02.005"},{"key":"e_1_2_1_108_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1007378"},{"key":"e_1_2_1_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61194-4"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70274-X"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-1-201101040-00289"},{"key":"e_1_2_1_112_2","unstructured":"Thompson Micromedex.Red book online. Dabigatran etexilate mesylate. Available fromhttp:www\u2010thomsonhc\u2010com.cuhsl.creighton.edumicromedex2librarian. AccessedMay 2 2011."},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1103050"},{"key":"e_1_2_1_114_2","unstructured":"U.S. Food and Drug Administration.Pradaxa capsules: special storage and handling requirements. Available fromhttp:www.fda.govSafetyMedWatchSafetyInformationSafetyAlertsforHumanMedicalProductsucm249005.htm. AccessedApril 15 2011."},{"key":"e_1_2_1_115_2","unstructured":"U.S. Food and Drug Administration.Boehringer Ingelheim advisory committee briefing document: dabigatran etexilate. August 27 2010. Available fromhttp:www.fda.govdownloadsAdvisoryCommitteesCommitteesMeetingMaterialsDrugsCardiovascularandRenalDrugsAdvisoryCommitteeucm226009.pdf. AccessedMay 25 2011."},{"key":"e_1_2_1_116_2","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1160\/TH08-09-0586","article-title":"Biochemical and pharmacological effects of the direct thrombin inhibitor AR\u2010H067637","volume":"101","author":"Deinum J.","year":"2009","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_117_2","volume-title":"Long\u2010term safety in atrial fibrillation patients. Updated 2009. ClinicalTrials.gov","author":"AstraZeneca.","year":"2011"},{"key":"e_1_2_1_118_2","volume-title":"Atrial fibrillation (AF) patients not taking vitamin\u2010K antagonist (VKA). Updated 2009. Clinical Trials.gov","author":"AstraZeneca.","year":"2011"},{"key":"e_1_2_1_119_2","unstructured":"ARYx Therapeutics.Comparison of ATI\u20105923 a novel vitamin K antagonist with warfarin in patients requiring chronic anticoagulation (EmbraceAC). Updated 2009. Available fromhttp:investors.aryx.comreleasedetail.cfmReleaseID394780. AccessedMay 5 2011."},{"key":"e_1_2_1_120_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.108.796185"},{"key":"e_1_2_1_121_2","unstructured":"Merck and Portola Pharmaceuticals.Phase 2 study showed investigational factor Xa inhibitor betrixaban reduced incidence of bleeding compared to warfarin in patients with atrial fibrillation. Press release March 15 2010. Available fromhttp:www.portola.compdfsBetrixaban_EXPLORE_ACC_032010.pdf. AccessedMay 8 2011."},{"key":"e_1_2_1_122_2","volume-title":"Study in healthy volunteers of the reversion by haemostatic drugs of the anticoagulant effect of new anti\u2010thrombotics (REVNEWANTICO). ClinicalTrials.gov","author":"University Hospital, Grenoble.","year":"2011"},{"key":"e_1_2_1_123_2","unstructured":"HackeW. PatelMR BeckerRC et al.Baseline characteristics of the ROCKET AF study: comparison with recent atrial fibrillation studies.Presented at the 19th European stroke conference Barcelona Spain May 2528 2010."},{"key":"e_1_2_1_124_2","first-page":"131","article-title":"Antithrombotic guideline adherence in atrial fibrillation patients admitted with stroke. Do we use our safety\u2010belt? European Society of Cardiology congress 2007 conference proceedings [abstract]","volume":"28","author":"Pisters R.","year":"2007","journal-title":"Eur Heart J"},{"key":"e_1_2_1_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2010.07.014"},{"key":"e_1_2_1_126_2","first-page":"e240","article-title":"Heart disease and stroke statistics\u20142011 update: a report from the American Heart Association","volume":"123","author":"Roger VL","year":"2010","journal-title":"Circulation"},{"key":"e_1_2_1_127_2","doi-asserted-by":"publisher","DOI":"10.2165\/11313800-000000000-00000"},{"key":"e_1_2_1_128_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-01-0071"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.31.10.975","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.31.10.975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:18:13Z","timestamp":1761045493000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.31.10.975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":127,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1592\/phco.31.10.975"],"URL":"https:\/\/doi.org\/10.1592\/phco.31.10.975","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}